ADC Therapeutics SA (ADCT) stock
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.30−0.07 (-5.11%)
Close on Nov 19, 2026Market cap $165.97MP/E –Yield –
ADC Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
ADC Therapeutics's gross profit for the twelve months ending Dec 31, 2023 was $67.03M, down 67.6% year over year. For fiscal 2025 it was $75.56M, up 16.4% from the year before. The highest annual figure on record is $206.61M in fiscal 2022.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.56M | +16.4% |
| FY2024 | Dec 31, 2024 | $64.89M | -3.2% |
| FY2023 | Dec 31, 2023 | $67.03M | -67.6% |
| FY2022 | Dec 31, 2022 | $206.61M | +535.2% |
| FY2021 | Dec 31, 2021 | $32.52M | – |
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $2.34M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $16.54M | -76.1% |
| Q3 FY2023 | Sep 30, 2023 | $14.13M | -81.2% |
| Q2 FY2023 | Jun 30, 2023 | $17.96M | +19.6% |
| Q1 FY2023 | Mar 31, 2023 | $18.40M | -60.0% |
| Q4 FY2022 | Dec 31, 2022 | $69.31M | +326.8% |
| Q3 FY2022 | Sep 30, 2022 | $75.03M | +493.3% |
| Q2 FY2022 | Jun 30, 2022 | $15.03M | +312.9% |
| Q1 FY2022 | Mar 31, 2022 | $45.97M | – |
| Q4 FY2021 | Dec 31, 2021 | $16.24M | – |
| Q3 FY2021 | Sep 30, 2021 | $12.65M | – |
| Q2 FY2021 | Jun 30, 2021 | $3.64M | – |
| Q1 FY2021 | Mar 31, 2021 | $0 | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
See a number that looks wrong?